drugset

drugset / Trial / NCT03136055

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055 ↗

Phase 2 Completed 36 enrolled University of California, San Francisco Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma

Timeline

Start: 2017-06-20
Primary completion: 2021-10-31
Completion: 2021-10-31

Publications

Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 Aug;129(2):291-300. doi: 10.1038/s41416-023-02298-8. Epub 2023 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	125 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	—	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Indications